Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The clinical effectiveness of parenterally-administered glucagon-like peptide-1 (GLP-1) mimetics to improve glucose control in patients suffering from type 2 diabetes strongly supports discovery pursuits aimed at identifying and developing orally active, small molecule GLP-1 receptor agonists. The purpose of these studies was to identify and characterize novel nonpeptide agonists of the GLP-1 receptor. RESEARCH DESIGN AND METHODS: Screening using cells expressing the GLP-1 receptor and insulin secretion assays with rodent and human islets were used to identify novel molecules. The intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo. RESULTS: Novel low molecular weight pyrimidine-based compounds that activate the GLP-1 receptor and stimulate glucose-dependent insulin secretion are described. These molecules induce GLP-1 receptor-mediated cAMP signaling in HEK293 cells expressing the GLP-1 receptor and increase insulin secretion from rodent islets in a dose-dependent manner. The compounds activate GLP-1 receptor signaling, both alone or in an additive fashion when combined with the endogenous GLP-1 peptide; however, these agonists do not compete with radiolabeled GLP-1 in receptor-binding assays. In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate increased insulin secretion in compound-treated animals. Further, perifusion assays with human islets isolated from a donor with type 2 diabetes show near-normalization of insulin secretion upon compound treatment. CONCLUSIONS: These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study showed that compound B almost normalised insulin secretion in human islets isolated from a T2D donor.286”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [286]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundAllosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
Background
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
“The pharmacology of a novel pyrimidine-based compound has recently been published by Sloop et al. (2010).”
BackgroundTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., et al. (2017) · Nature · doi:10.1038/nature22378 · Cited by 241
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundSelf-citationCoumarins as potential antidiabetic agents
Li, H., Yao, Y., & Li, L. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12774 · Cited by 202
“GLP-1 receptor agonists (exenatide) stimulate insulin secretion([12]) and also regulate pancreatic endocrine cells growth and differentiation.”
BackgroundManandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“With the promising results seen with GLP1R agonists [130], the next generations of diabetes drugs will likely focus on the alternate delivery for injectables as illustrated by recent experience with GLP-1 analogs and insulin [131–134] and the combined activation of more than one receptor [135].”
BackgroundTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
Bailey, C. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.144 · Cited by 102
“Several small molecules that activate GLP-1 receptors have received preliminary investigation in vitro and in animal models.(37)”
BackgroundMolecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
Cong, Z., Chen, L.-N., Ma, H., Zhou, Q., Zou, X., Ye, C., Dai, A., Liu, Q., Huang, W., Sun, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24058-z · Cited by 89
Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
Bueno, A. B., Sun, B., Willard, F. S., Feng, D., Ho, J. D., Wainscott, D. B., Showalter, A. D., Vieth, M., Chen, Q., Stutsman, C., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0589-7 · Cited by 98
Self-citationDeepCPI: A Deep Learning-Based Framework for Large-Scale in Silico Drug Screening
Wan, F., Zhu, Y., Hu, H., Dai, A., Cai, X., Chen, L., Gong, H., Xia, T., Yang, D., Wang, M.-W., et al. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.04.003 · Cited by 92
“…suggest that the binding sites of our predicted PAMs are located deeper inside the transmembrane domain of GLP-1R than that of the known covalently bound PAMs, including Compound 2 [59] and 4-(3-(benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluorome thyl)pyrimidine (BETP) [60,61] (Figures 6A and S7).”
A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1581 · Cited by 86
Wootten, D. L., Savage, E. E., Willard, F. S., Bueno, A. B., Sloop, K. W., Christopoulos, A., & Sexton, P. M. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084525 · Cited by 91
“In this study, the selective GLP-1R small molecules, BETP (Sloop et al., 2010), Compound 2 (Knudsen et al.”
BackgroundSelf-citationWootten, D. L., Simms, J., Koole, C., Woodman, O. L., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176362 · Cited by 90
“These include a series of substituted quinoxalines, the most potent of which is compound 2 (Knudsen et al., 2007; Teng et al., 2007), a series of pyrimidines (Sloop et al., 2010), and a cyclobutane derivative (Chen et al., 2007).”
BackgroundSmall Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
Willard, F. S., Bueno, A. B., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/709893 · Cited by 81
“Our group identified a series of pyrimidine based ago-allosteric modulators of the GLP-1 receptor exemplified by racemic compound 13 (Figure 2, (13) 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl) pyrimidine; BETP) [13].”
BackgroundSelf-citationMyricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist
Li, Y., Zheng, X., Yi, X., Liu, C., Kong, D., Zhang, J., & Gong, M. (2017) · The FASEB Journal · doi:10.1096/fj.201601339r · Cited by 98
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors
Gong, N., Fan, H. J., Ma, A., Xiao, Q., & Wang, Y. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.007 · Cited by 83
“It has been reported that substituted cyclobutanes such as Boc5 and BW4-24 (Chen et al., 2007; Liu et al., 2012) and pyrimidines such as Compound B (Sloop et al., 2010) are orthosteric agonists, whereas 6,7-dichloroquinoxalines (Irwin et al., 2010; Teng et al., 2007) and Compound 2 (Knudsen et al.,…”
Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function
Koole, C., Pabreja, K., Savage, E. E., Wootten, D., Furness, S. G. B., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120236 · Cited by 75
Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery
Wootten, D. L., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., FICORILLI, J. V., Showalter, A. D., Willard, F. S., Christopoulos, A., & Sexton, P. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079319 · Cited by 78
“However, it is not uncommon to require much larger doses of hormones in ex vivo experiments compared with in vivo, for example, the EC50 for GLP-1(7–36)NH2 stimulation of islet culture insulin release is 1 to 10 nM (Göke et al., 1993; Sloop et al., 2010; Tomas et al., 2010), only 10-fold lower than the augmented metab…”
BackgroundMethodResultInfluentialSelf-citationGLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
Thompson, A., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.015 · Cited by 82
“As observed previously by other studies [36–40], both small-molecule agonists have induced cAMP production but not intracellular Ca accumulation or ERK phosphorylation.”
BackgroundResultHarikumar, K. G., Wootten, D., Pinon, D. I., Koole, C., Ball, A. M., Furness, S. G. B., Graham, B., Dong, M., Christopoulos, A., Miller, L. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205227109 · Cited by 73
“The use of two chemically distinct modulators, compound 2 from NovoNordisk (30) and BETP from Eli Lilly (40), confirmed that this is likely to be a generalized feature of allosteric modulation of the GLP-1R.”
BackgroundProglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Zhao, L., Yin, Y., Yang, D., Liu, B., Hou, L., Wang, X., Pal, K., Jiang, Y., Feng, Y., Cai, X., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.726620 · Cited by 71
“In contrast, the pyrimidine BETP (31) was not competed by exendin(9 –39) or GLP-1 and is, therefore, thought to allosterically activate GLP-1R (31–34).”
BackgroundInfluentialDesign, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates
Han, J. D. J., Sun, L., Chu, Y., Li, Z., Huang, D., Zhu, X., Qian, H., & Huang, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4017448 · Cited by 78
Therapeutic Targets for Diabetes Mellitus: An Update
Tiwari, N. (2014) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.1000117 · Cited by 71
“Researchers from various biomedical areas are in search of non-peptide drugs which activate the insulin receptors [78,79].”
BackgroundPositive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
Bueno, A. B., Showalter, A. D., Wainscott, D. B., Stutsman, C., Marín, A., Ficorilli, J., Cabrera, O., Willard, F. S., & Sloop, K. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696039 · Cited by 59
“BETP is an electrophilic small molecule that enhances GLP-1R signaling (19, 22) by binding covalently to Cys-347 within the third intracellular loop of the receptor (26).”
BackgroundSelf-citationInvestigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
Weston, C., Poyner, D., Patel, V, Dowell, S., & Ladds, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12716 · Cited by 53
“These molecules have been shown to bind to the receptor in allosteric sites each having differing agonist affects on GLP-1 receptor-mediated cAMP accumulation (Knudsen et al., 2007; Sloop et al., 2010).”
BackgroundResultInfluentialOleoylethanolamide: A fat ally in the fight against obesity
Brown, J. D., Azari, E. K., & Ayala, J. E. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.034 · Cited by 62
Willard, F. S., Wootten, D. L., Showalter, A. D., Savage, E. E., FICORILLI, J. V., Farb, T. B., Bokvist, K. B., Alsina‐Fernandez, J., Furness, S. G. B., Christopoulos, A., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080432 · Cited by 53
Self-citationHan, J. D. J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H., & Huang, W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12843 · Cited by 54
“HEK293 cells stably expressing human GLP-1 receptor were used for measurement of intracellular cAMP (Sloop et al., 2010).”
MethodKnerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Han, J. D. J., Huang, X., Sun, L., Li, Z., Qian, H., & Huang, W. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.05.012 · Cited by 47
Chen, Z.-Y., Liu, S.-N., Li, C.-N., Sun, S.-J., Liu, Q., Lei, L., Gao, L.-H., & Shen, Z.-F. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-98 · Cited by 46
“Hyperglycemic studies were conducted as described previously [42].”
Metabolic Disease Drug Discovery— “Hitting the Target” Is Easier Said Than Done
Moller, D. E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.012 · Cited by 47
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“by BETP was identified by screening a small library generated through a pharmacophore model [116].”
MethodKoole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
King, K., Lin, N.-P., Cheng, R. Y.-H., Chen, G.-H., & Chein, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672097 · Cited by 44
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
The complexity of signalling mediated by the glucagon-like peptide-1 receptor
Fletcher, M. M., Halls, M. L., Christopoulos, A., Sexton, P. M., & Wootten, D. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150244 · Cited by 39
Structural Basis for Allosteric Modulation of Class B G Protein–Coupled Receptors
Wootten, D. L., & Miller, L. J. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023301 · Cited by 42
“The best understood small molecule PAM-agonists of the GLP-1 receptor include quinoxalines, such as compound 2 (59), pyrimidines, such as BETP/compound B (60), and substituted cyclobutanes, such as Boc5 (1,3-bis[[4-tert-butoxycarbonylamino)benzoyl]amino]-2,4-bis[3-methoxy-4-(thiophene-2-carbonyloxy)phenyl]cyclobutane-…”
Koole, C., Wootten, D. L., Simms, J., Savage, E. E., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309369 · Cited by 42
He, M., Guan, N., Gao, W.-W., Liu, Q., Wu, X.-Y., Ma, D.-W., Zhong, D.-F., Ge, G.-B., Li, C., Chen, X.-Y., et al. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.169 · Cited by 36
Actions of the Small Molecule Ligands SW106 and AH-3960 on the Type-1 Parathyroid Hormone Receptor
Carter, P. H., Dean, T., Bhayana, B., Khatri, A., Rajur, R., & Gardella, T. J. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1129 · Cited by 34
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33
“Further studies showed treatment with compound B to near-normalise insulin secretion with human islets isolated from a donor with type 2 diabetes [162].”
BackgroundJun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32
“Detailed protocols for islet studies as well as the cAMP accumulation assays are previously described [27,28].”
MethodSelf-citationGirdhar, K., Dehury, B., Singh, M. K., Daniel, P. V., Choubey, A., Dogra, S., Kumar, S., & Mondal, P. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1532818 · Cited by 33
“Methods that were used till now for the screening of the above GLP-1R agonist are time-consuming and cost ineffective (Knudsen et al., 2007; Morris et al., 2014; Sloop et al., 2010; Wang, Liu, & Zhou, 2010).”
BackgroundMethodResultYin, Y., Zhou, X. E., Hou, L., Zhao, L., Liu, B., Wang, G., Jiang, Y., Melcher, K., & Xu, H. E. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.42 · Cited by 31
Janssens, J., Etienne, H., Idriss, S., Azmi, A., Martin, B., & Maudsley, S. R. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00142 · Cited by 32
Eng, H. F., Sharma, R., McDonald, T. S., Edmonds, D. J., Fortin, J., Li, X., Stevens, B. D., Griffith, D. A., Limberakis, C., Nolte, W. M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052183 · Cited by 30
“With reference to the glucose-dependent insulin secretion noted over a course of ;20 minutes after a single i.v. bolus dose of BETP at 10 mg/kg (Sloop et al., 2010), it is possible that enough BETP systemic exposure was achieved at the i.v. dose of 10 mg/kg to cover the in vitro EC50 of 0.75 mM of…”
BackgroundInfluentialNoroozzadeh, M., Tehrani, F. R., Sedaghat, K., Godini, A., & Azizi, F. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0198-y · Cited by 30
Karbalaei, N., Ghasemi, A., Hedayati, M., Godini, A., & Zahediasl, S. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.073825 · Cited by 28
“Glucose (0.5 mg (g body weight)−1; Sloop et al. 2010) was administered via I.V. injection, and blood samples were collected by tail cut before (0 min) and 5, 10, 15, 20, 30 and 60 min after glucose administration.”
MethodInfluentialPro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28
“Some agonists have been reported but they have low efficiency compared with GLP-1 (Sloop et al., 2010).”
BackgroundPharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Decara, J. M., Vázquez‐Villa, H., Brea, J. M., Alonso, M., Srivastava, R. K., Orío, L., Alén, F., Suárez, J., Baixerás, E., García-Cárceles, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01842 · Cited by 26
Shang, J., Yan, W., Cui, X. Y., Ma, W., Wang, Z., Liu, N., Yi, X., Guo, T., Wei, X., Sun, Y., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112029 · Cited by 28
Singh, R. K., Ahalawat, N., & Murarka, R. K. (2015) · The Journal of Physical Chemistry B · doi:10.1021/jp509814n · Cited by 25
Moon, M. J., Lee, Y.-N., Park, S., Reyes‐Alcaraz, A., Hwang, J., Millar, R. P., Choe, H., & Seong, J. Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612606 · Cited by 25
“Thus, there is a great need to develop orally active small molecules that can act on GLP1R (10, 11).”
BackgroundChen, L., Yun, Y., Guo, S., Wang, X., Xiong, M., Zhao, T., Xu, T., Shen, J., Xie, X., & Wang, K. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00320 · Cited by 24
Moon, M. J., Kim, H. Y., Park, S., Kim, D.-K., Cho, E. B., Park, C. R., You, D., Hwang, J., Kim, K., Choe, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276808 · Cited by 23
“Because the ligand binding site within the TMH core can be considered as a target of nonpeptide ligands (45, 46), our study may facilitate molecular modeling of the ligand-bound receptor structure followed by extensive medicinal chemistry.”
BackgroundSun, L., Huang, X., Han, J. D. J., Cai, X., Dai, Y., Chu, Y., Wang, C., Huang, W., & Qian, H. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.016 · Cited by 23
New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs
Gilor, C., Rudinsky, A. J., & Hall, M. J. (2016) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x16660441 · Cited by 26
Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site
Wang, J., Yang, D., Cheng, X., Yang, L., Wang, Z., Dai, A., Cai, X., Zhang, C., Yuliantie, E., Liu, Q., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00552 · Cited by 24
Ge, G., Ai, C., Hu, W., Hou, J., Zhu, L., He, G.-Y., Fang, Z., Liang, S., Wang, F., & Yang, L. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.11.011 · Cited by 25
“Although it has been well accepted that the glucose responsiveness of rodents and human islets are similar and mouse is always selected to set the T2DM model for in vivo pharmacological assessment (Sloop et al., 2010; Su et al. 2008), our findings suggest that mouse is not ideal model for in vivo pharmacological asses…”
BackgroundFuselier, T. T., de Sa, P. M., Qadir, M. M. F., Xu, B., Allard, C., Meyers, M. M., Tiano, J. P., Yang, B. S., Gelfanov, V. M., Lindsey, S. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100598 · Cited by 25
“To test whether the mechanism of cellular entry of GLP1-E2 peptides involvesGLP-1R internalization, we treated ERE-GFPMIN6 cells withGLP1-E2 in the presence of BETP (also known as compound B), a selective GLP-1R allosteric modulator and agonist that impairs GLP-1R internalization.(29,30) Under these conditions, BETP a…”
MethodGermano, J. D. F., Huang, C., Sin, J., Song, Y., Tucker, K. C., Taylor, D. J. R., Saadaeijahromi, H., Stotland, A. B., Piplani, H., Gottlieb, R. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64924-2 · Cited by 21
Sato, K., Nakamura, A., Shirakawa, J., Muraoka, T., Togashi, Y., Shinoda, K., Orime, K., Kubota, N., Kadowaki, T., & Terauchi, Y. (2012) · Endocrinology · doi:10.1210/en.2011-1712 · Cited by 20
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
Redij, T., Chaudhari, R. R., Li, Z., Hua, X., & Li, Z. (2019) · ACS Omega · doi:10.1021/acsomega.8b03052 · Cited by 23
“− 8 However, the lack of a high-quality structure of the TM domain of GLP-1R until very recently 23 − 25 hindered further development of these lead compounds into drugs.”
Šmelcerović, A., Lazarević, J., Tomović, K., Anastasijevic, M., Jukič, M., Kocic, G. M., & Anderluh, M. (2019) · ChemMedChem · doi:10.1002/cmdc.201800699 · Cited by 20
Miller, L. J., Sexton, P. M., Dong, M., & Harikumar, K. G. (2014) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2014.4 · Cited by 24
AlNeyadi, S. S., Amir, N., Ghattas, M. A., Atatreh, N., Alketbi, S., Ajeil, R. A., & Adem, A. (2020) · Molecules · doi:10.3390/molecules25184313 · Cited by 18
“Sloop et al [19]. showed that two pyrimidine/quinoxaline-based compounds act on the GLP-1 receptor as allosteric agonists.”
BackgroundResultInfluentialYe, X., Liu, S., Liu, Y., Qian, Z., Liu, H., Zhang, B., Guo, T., Thompson, G. J., Stevens, R. C., Sharpless, K. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220767120 · Cited by 17
“2220767120 3 of 11 presence of the endogenous peptide GLP-1(9-36).”
BackgroundMethodInfluentialYang, D., Zhou, C., Liu, Q., & Wang, M. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.78 · Cited by 18
Treating obesity: is it all in the gut?
Davenport, R. J., & Wright, S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.025 · Cited by 21
Willard, F. S., Ho, J. D., & Sloop, K. W. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.001 · Cited by 17
Self-citationCheong, Y.-H., Kim, M.-K., Son, M.-H., & Kaang, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.004 · Cited by 17
Brown, J. D., McAnally, D., Ayala, J. E., Burmeister, M. A., Morfa, C. J., Smith, L. H., & Ayala, J. E. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00459.2017 · Cited by 20
A facile method for the synthesis of pyridazino[4,5-b][1,4]thiazine-diones via Smiles rearrangement
Zhao, Y., Bai, Y., Zhang, Q., Chen, Z., Dai, Q., & Ma, C. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.04.026 · Cited by 16
Zheng, W., Li, L., & Li, H. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114817 · Cited by 16
Sun, L., Wang, C., Dai, Y., Chu, Y., Han, J. D. J., Zhou, J., Cai, X., Huang, W., & Qian, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.028 · Cited by 15
Discovery of small molecule positive allosteric modulators of the secretin receptor
Dengler, D. G., Harikumar, K. G., Pollari, S., Sun, Q. Y., Brown, B. T., Shinoki-Iwaya, A., Ardecky, R., Miller, L. J., & Sergienko, E. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114451 · Cited by 15
Drug discovery approaches targeting the incretin pathway
Deng, X., Tavallaie, M. S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., & Jiang, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103810 · Cited by 15
Aktar, B. S. K., Sıcak, Y., Bakırdöven, A., Tatar, G., Yılmaz, Ö., Karaküçük‐İyidoğan, A., Taşdemir, D., Sağlam, E., & Oruç‐Emre, E. E. (2025) · ACS Omega · doi:10.1021/acsomega.4c10095 · Cited by 16
Luo, X., Pan, L., Nie, A., Wang, Q., Gu, Y., Li, F., Zhang, H., Li, W., & Li, X. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12061 · Cited by 14
Redij, T., Ma, J., Li, Z., Hua, X., & Li, Z. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00254-4 · Cited by 16
Girdhar, K., Thakur, S., Gaur, P., Choubey, A., Dogra, S., Dehury, B., Kumar, S., Biswas, B., Dwivedi, D. K., Ghosh, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101889 · Cited by 14
“To overcome these limitations of peptide agonists of GLP1R, many small molecule GLP1R agonists like 2-(2-methyl) thiadiazolylsulfanyl-3- trifluoromethyl-6,7-dichloroquinoxaline (compound 1), 6,7-dichloro-2-methylsulfonyl-3-N-tertbutylaminoquinoxaline (compound 2) (6), pyrimidine, 4-(3,4dichlorophenyl)-2-(ethylsulfonyl…”
BackgroundMorris, L. C., Days, E., Turney, M. K., Mi, D., Lindsley, C. W., Weaver, C. D., & Niswender, K. D. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114520971 · Cited by 14
“The GLP-1R belongs to the class-B GPCR family and binds four different forms of endogenous GLP-1 peptide— GLP-1(1-37), GLP-1(7-37), GLP-1(1-36)NH2, and GLP1(7-36)NH2—and a structurally related peptide, oxyntomodulin.”
BackgroundLi, Y., Cui, T., Kong, X., Yi, X., Kong, D., Zhang, J., Liu, C., & Gong, M. (2018) · The FASEB Journal · doi:10.1096/fj.201701033rrr · Cited by 14
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Metadata
- Authors
- Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., & Coghlan, M. J.
- Affiliations
- Eli Lilly (United States) (US)
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
- Corresponding author
- Sloop, Kyle W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-09-07
- Volume
- 59
- Issue
- 12
- Pages
- 3099-3107
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2992771
- OpenAlex
- W2142458050
- Cited by
- 143
- References
- 35
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 12 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 10 · 2015: 10 · 2014: 17 · 2013: 19 · 2012: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor agonists, small molecule agonists, insulin secretion, type 2 diabetes, pyrimidine derivatives, cAMP signaling, glucose-dependent insulin secretion, human pancreatic islets, oral GLP-1 receptor agonists, drug discovery
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Cyclic AMP, Animals, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Luciferases, Male, Parathyroid Hormone, Vasoactive Intestinal Peptide, Rats, Sprague-Dawley, Genes, Reporter, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.